Journal article
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
- Abstract:
- Follicular lymphoma (FL) is an indolent B-cell malignancy with a variable course. Standard immuno-chemotherapy incorporate alkylator and anti-CD20 monoclonal antibody as first line (Rummel et al, 2013) commonly followed by 24 months rituximab maintenance (Salles et al, 2008). Anthracycline, purine analogue, and alkylator combination are used at relapse and younger patients may have remissions consolidated with autologous or allogeneic stem-cell transplantation (alloSCT) (Kothari et al, 2014). Relapsed or refractory (R/R) FL in patients unfit for transplantation or post-transplantation is incurable, and remains an unmet need.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 361.9KB, Terms of use)
-
- Publisher copy:
- 10.1111/bjh.14665
Authors
- Publisher:
- Wiley
- Journal:
- British Journal of Haematology More from this journal
- Publication date:
- 2017-03-01
- Acceptance date:
- 2017-02-27
- DOI:
- EISSN:
-
1365-2141
- ISSN:
-
0007-1048
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:688793
- UUID:
-
uuid:03900685-578c-4839-add9-e27317d4b964
- Local pid:
-
pubs:688793
- Source identifiers:
-
688793
- Deposit date:
-
2017-05-26
Terms of use
- Copyright holder:
- John Wiley et al
- Copyright date:
- 2017
- Notes:
- © 2017 John Wiley and Sons Ltd. This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1111/bjh.14665
If you are the owner of this record, you can report an update to it here: Report update to this record